|
1
|
Xu N and Dahlbäck B: A novel human
apolipoprotein (apoM). J Biol Chem. 274:31286–31290. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Christoffersen C, Nielsen LB, Axler O,
Andersson A, Johnsen AH and Dahlbäck B: Isolation and
characterization of human apolipoprotein M-containing lipoproteins.
J Lipid Res. 47:1833–1843. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Axler O, Ahnström J and Dahlbäck B: An
ELISA for apolipoprotein M reveals a strong correlation to total
cholesterol in human plasma. J Lipid Res. 48:1772–1780. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang XY, Dong X, Zheng L, et al: Specific
tissue expression and cellular localization of human apolipoprotein
M as determined by in situ hybridization. Acta Histochem.
105:67–72. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang XY, Jiao GQ, Hurtig M, et al:
Expression pattern of apolipoprotein M during mouse and human
embryogenesis. Acta Histochem. 106:123–128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Faber K, Axler O, Dahlbäck B and Nielsen
LB: Characterization of apoM in normal and genetically modified
mice. J Lipid Res. 45:1272–1278. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flower DR, North AC and Attwood TK:
Structure and sequence relationships in the lipocalins and related
proteins. Protein Sci. 2:753–761. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorenson RC, Bisgaier CL, Aviram M, Hsu C,
Billecke S and La Du BN: Human serum Paraoxonase/Arylesterase’s
retained hydrophobic N-terminal leader sequence associates with
HDLs by binding phospholipids: apolipoprotein A-I stabilizes
activity. Arterioscler Thromb Vasc Biol. 19:2214–2225. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Axler O, Ahnström J and Dahlbäck B:
Apolipoprotein M associates to lipoproteins through its retained
signal peptide. FEBS Lett. 582:826–828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duan J, Dahlbäck B and Villoutreix BO:
Proposed lipocalin fold for apolipoprotein M based on
bioinformatics and site-directed mutagenesis. FEBS Lett.
499:127–132. 2001. View Article : Google Scholar
|
|
11
|
Christoffersen C, Ahnström J, Axler O,
Christensen EI, Dahlbäck B and Nielsen LB: The signal peptide
anchors apolipoprotein M in plasma lipoproteins and prevents rapid
clearance of apolipoprotein M from plasma. J Biol Chem.
283:18765–18772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Flower DR, North AC and Sansom CE: The
lipocalin protein family: structural and sequence overview. Biochim
Biophys Acta. 1482:9–24. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sevvana M, Ahnström J, Egerer-Sieber C,
Lange HA, Dahlbäck B and Muller YA: Serendipitous fatty acid
binding reveals the structural determinants for ligand recognition
in apolipoprotein M. J Mol Biol. 393:920–936. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ahnström J, Faber K, Axler O and Dahlbäck
B: Hydrophobic ligand binding properties of the human lipocalin
apolipoprotein M. J Lipid Res. 48:1754–1762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Christoffersen C, Obinata H, Kumaraswamy
SB, et al: Endothelium-protective sphingosine-1-phosphate provided
by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA.
108:9613–9618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faber K, Hvidberg V, Moestrup SK, Dahlbäck
B and Nielsen LB: Megalin is a receptor for apolipoprotein M and
kidney-specific megalin-deficiency confers urinary excretion of
apolipoprotein M. Mol Endocrinol. 20:212–218. 2006. View Article : Google Scholar
|
|
17
|
Karlsson H, Lindqvist H, Tagesson C and
Lindahl M: Characterization of apolipoprotein M isoforms in
low-density lipoprotein. J Proteome Res. 5:2685–2690. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tetaz T, Detzner S, Friedlein A, Molitor B
and Mary JL: Hydrophilic interaction chromatography of intact,
soluble proteins. J Chromatogr A. 1218:5892–5896. 2011. View Article : Google Scholar
|
|
19
|
Xu N, Zhang XY, Dong X, Ekström U, Ye Q
and Nilsson-Ehle P: Effects of platelet-activating factor, tumor
necrosis factor and interleukin-1alpha on the expression of
apolipoprotein M in HepG2 cells. Biochem Biophys Res Commun.
292:944–950. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu N, Hurtig M, Zhang XY, Ye Q and
Nilsson-Ehle P: Transforming growth factor-beta down-regulates
apolipoprotein M in HepG2 cells. Biochim Biophys Acta. 1683:33–37.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Swenson ES, Guest I, Ilic Z, et al:
Hepatocyte nuclear factor-1 as marker of epithelial phenotype
reveals marrow-derived hepatocytes, but not duct cells, after liver
injury in mice. Stem Cells. 26:1768–1777. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Richter S, Shih DQ, Pearson ER, et al:
Regulation of apolipoprotein M gene expression by MODY3 gene
hepatocyte nuclear factor-1alpha: haploinsufficiency is associated
with reduced serum apolipoprotein M levels. Diabetes. 52:2989–2995.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shih DQ, Bussen M, Sehayek E, et al:
Hepatocyte nuclear factor-1alpha is an essential regulator of bile
acid and plasma cholesterol metabolism. Nat Genet. 27:375–382.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mosialou I, Krasagakis K and Kardassis D:
Opposite regulation of the human apolipoprotein M gene by
hepatocyte nuclear factor 1 and Jun transcription factors. J Biol
Chem. 286:17259–17269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Venteclef N, Haroniti A, Tousaint JJ,
Talianidis I and Delerive P: Regulation of anti-atherogenic
apolipoprotein M gene expression by the orphan nuclear receptor
LRH-1. J Biol Chem. 283:3694–3701. 2008. View Article : Google Scholar
|
|
26
|
Zhang Y and Mangelsdorf DJ: LuXuRies of
lipid homeostasis: the unity of nuclear hormone receptors,
transcription regulation, and cholesterol sensing. Mol Interv.
2:78–87. 2002. View Article : Google Scholar
|
|
27
|
Zhang Y, Chen CJ, Yang QL, Cheng LQ, Wang
H and Huang LZ: Effect of interfering hepatocyte nuclear factor-1
alfa in HepG2 on the expressions of apoM, apoA-I and the
correlative key enzyme of cholesterol metabolism. Zhonghua Gan Zang
Bing Za Zhi. 19:121–126. 2011.In Chinese. PubMed/NCBI
|
|
28
|
Calayir E, Becker TM, Kratzer A, et al:
LXR-agonists regulate ApoM expression differentially in liver and
intestine. Curr Pharm Biotechnol. 9:516–521. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fielding CJ and Fielding PE: Cellular
cholesterol efflux. Biochim Biophys Acta. 1533:175–189. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Di D, Wang Z, Liu Y, et al: ABCA1
upregulating apolipoproein M expression mediates via the RXR/lXR
pathway in HepG2 cells. Biochem Biophys Res Commun. 421:152–156.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang X, Zhu Z, Luo G, Zheng L,
Nilsson-Ehle P and Xu N: Liver X receptor agonist downregulates
hepatic apoM expression in vivo and in vitro. Biochem Biophys Res
Commun. 371:114–117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mosialou I, Zannis VI and Kardassis D:
Regulation of human apolipoprotein m gene expression by orphan and
ligand-dependent nuclear receptors. J Biol Chem. 285:30719–30730.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yi-Zhou Y, Guo Qing J, Jian Z, et al:
Dihydrotestosterone regulating apolipoprotein M expression mediates
via protein kinase C in HepG2 cells. Lipids Health Dis. 11:1682012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Silver DL, Jiang XC, Arai T, Bruce C and
Tall AR: Receptors and lipid transfer proteins in HDL metabolism.
Ann NY Acad Sci. 902:103–111. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stein O and Stein Y: Atheroprotective
mechanisms of HDL. Atherosclerosis. 144:285–301. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Assmann G and Nofer JR: Atheroprotective
effects of high-density lipoproteins. Annu Rev Med. 54:321–341.
2003. View Article : Google Scholar
|
|
37
|
Phillips MC, Gillotte KL, Haynes MP,
Johnson WJ, Lund-Katz S and Rothblat GH: Mechanisms of high density
lipoprotein-mediated efflux of cholesterol from cell plasma
membranes. Atherosclerosis. 137(Suppl): 13–17. 1998. View Article : Google Scholar
|
|
38
|
Santamarina-Fojo S, Lambert G, Hoeg JM and
Brewer HB Jr: Lecithin-cholesterol acyltransferase: role in
lipoprotein metabolism, reverse cholesterol transport and
atherosclerosis. Curr Opin Lipidol. 11:267–275. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sparks DL and Pritchard PH: Transfer of
cholesteryl ester into high density lipoprotein by cholesteryl
ester transfer protein: effect of HDL lipid and apoprotein content.
J Lipid Res. 30:1491–1498. 1989.PubMed/NCBI
|
|
40
|
Christoffersen C, Pedersen TX, Gordts PL,
Roebroek AJ, Dahlbäck B and Nielsen LB: Opposing effects of
apolipoprotein m on catabolism of apolipoprotein B-containing
lipoproteins and atherosclerosis. Circ Res. 106:1624–1634. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Christoffersen C, Jauhiainen M, Moser M,
et al: Effect of apolipoprotein M on high density lipoprotein
metabolism and atherosclerosis in low density lipoprotein receptor
knock-out mice. J Biol Chem. 283:1839–1847. 2008. View Article : Google Scholar
|
|
42
|
Wolfrum C, Poy MN and Stoffel M:
Apolipoprotein M is required for prebeta-HDL formation and
cholesterol efflux to HDL and protects against atherosclerosis. Nat
Med. 11:418–422. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ahnström J, Axler O, Jauhiainen M, et al:
Levels of apolipoprotein M are not associated with the risk of
coronary heart disease in two independent case-control studies. J
Lipid Res. 49:1912–1917. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rye KA, Duong M, Psaltis MK, et al:
Evidence that phospholipids play a key role in pre-beta apoA-I
formation and high-density lipoprotein remodeling. Biochemistry.
41:12538–12545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Christoffersen C, Jauhiainen M, Moser M,
et al: Effect of apolipoprotein M on high density lipoprotein
metabolism and atherosclerosis in low density lipoprotein receptor
knock-out mice. J Biol Chem. 283:1839–1847. 2008. View Article : Google Scholar
|
|
46
|
Elsøe S, Ahnström J, Christoffersen C, et
al: Apolipoprotein M binds oxidized phospholipids and increases the
antioxidant effect of HDL. Atherosclerosis. 221:91–97. 2012.
View Article : Google Scholar
|
|
47
|
Elsøe S, Christoffersen C, Luchoomun J,
Turner S and Nielsen LB: Apolipoprotein M promotes mobilization of
cellular cholesterol in vivo. Biochim Biophys Acta. 1831:1287–1292.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang XS, Zhao SP, Hu M and Luo YP:
Apolipoprotein M likely extends its anti-atherogenesis via
anti-inflammation. Med Hypotheses. 69:136–140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Christoffersen C and Nielsen LB:
Apolipoprotein M-a new biomarker in sepsis. Crit Care. 16:1262012.
View Article : Google Scholar
|
|
50
|
Kumaraswamy SB, Linder A, Akesson P and
Dahlbäck B: Decreased plasma concentrations of apolipoprotein M in
sepsis and systemic inflammatory response syndromes. Crit Care.
16:R602012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sattler KJ, Elbasan S, Keul P, et al:
Sphingosine 1-phosphate levels in plasma and HDL are altered in
coronary artery disease. Basic Res Cardiol. 105:821–832. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Arkensteijn BW, Berbée JF, Rensen PC,
Nielsen LB and Christoffersen C: The apolipoprotein
m-sphin-gosine-1-phosphate axis: biological relevance in
lipoprotein metabolism, lipid disorders and atherosclerosis. Int J
Mol Sci. 14:4419–4431. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kurano M, Tsukamoto K, Ohkawa R, et al:
Liver involvement in sphingosine 1-phosphate dynamism revealed by
adenoviral hepatic overexpression of apolipoprotein M.
Atherosclerosis. 229:102–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xu WW, Zhang Y, Tang YB, et al: A genetic
variant of apolipoprotein M increases susceptibility to coronary
artery disease in a Chinese population. Clin Exp Pharmacol Physiol.
35:546–551. 2008. View Article : Google Scholar
|
|
55
|
Jiao GQ, Yuan ZX, Xue YS, et al: A
prospective evaluation of apolipoprotein M gene T-778C polymorphism
in relation to coronary artery disease in Han Chinese. Clin
Biochem. 40:1108–1112. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang Z, Chu G and Yin RX: Apolipoprotein
M T-778C polymorphism is associated with serum lipid levels and the
risk of coronary artery disease in the Chinese population: a
meta-analysis. Lipids Health Dis. 12:1352013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brorsson C, Hansen NT, Lage K, Bergholdt
R, Brunak S and Pociot F; Diabetes Genetics Consortium:
Identification of T1D susceptibility genes within the MHC region by
combining protein interaction networks and SNP genotyping data.
Diabetes Obes Metab. 11(Suppl 1): 60–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu X, Niu N, Brismar K, et al:
Apolipoprotein M promoter polymorphisms alter promoter activity and
confer the susceptibility to the development of type 1 diabetes.
Clin Biochem. 42:17–21. 2009. View Article : Google Scholar
|
|
59
|
Zhou JW, Tsui SK, Ng MC, et al:
Apolipoprotein M gene (APOM) polymorphism modifies metabolic and
disease traits in type 2 diabetes. PLoS One. 6:e173242011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang YY, Proenca R, Margherita M, et al:
Positional cloning of the mouse obese gene and its human homologue.
Nature. 372:425–432. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ahima RS and Flier JS: Leptin. Annu Rev
Physiol. 62:413–437. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Xu N, Nilsson-Ehle P and Ahrén B:
Correlation of apolipoprotein M with leptin and cholesterol in
normal and obese subjects. J Nutr Biochem. 15:579–582. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xu N, Nilsson-Ehle P, Hurtig M and Ahrén
B: Both leptin and leptin-receptor are essential for apolipoprotein
M expression in vivo. Biochem Biophys Res Commun. 321:916–921.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Luo G, Hurtig M, Zhang X, Nilsson-Ehle P
and Xu N: Leptin inhibits apolipoprotein M transcription and
secretion in human hepatoma cell line, HepG2 cells. Biochim Biophys
Acta. 1734:198–202. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ooi EM, Watts GF, Chan DC, et al:
Association of apolipoprotein M with high-density lipoprotein
kinetics in overweight-obese men. Atherosclerosis. 210:326–330.
2010. View Article : Google Scholar
|
|
66
|
Kappelle PJ, Lambert G, Dahlbäck B,
Nielsen LB and Dullaart RP: Relationship of plasma apolipoprotein M
with proprotein convertase subtilisin-kexin type 9 levels in
non-diabetic subjects. Atherosclerosis. 214:492–494. 2011.
View Article : Google Scholar
|
|
67
|
Cervin C, Axler O, Holmkvist J, et al: An
investigation of serum concentration of apoM as a potential MODY3
marker using a novel ELISA. J Intern Med. 267:316–321. 2010.
View Article : Google Scholar
|
|
68
|
Mughal SA, Park R, Nowak N, et al:
Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
Diabet Med. 30:246–250. 2013. View Article : Google Scholar
|
|
69
|
Xu N, Nilsson-Ehle P and Ahrén B:
Suppression of apolipoprotein M expression and secretion in
alloxan-diabetic mouse: Partial reversal by insulin. Biochem
Biophys Res Commun. 342:1174–1177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang X, Jiang B, Luo G, Nilsson-Ehle P
and Xu N: Hyperglycemia down-regulates apolipoprotein M expression
in vivo and in vitro. Biochim Biophys Acta. 1771:879–882. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Xu N, Ahrén B, Jiang J and Nilsson-Ehle P:
Down-regulation of apolipoprotein M expression is mediated by
phosphatidylinositol 3-kinase in HepG2 cells. Biochim Biophys Acta.
1761:256–260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wolfrum C, Howell JJ, Ndungo E and Stoffel
M: Foxa2 activity increases plasma high density lipoprotein levels
by regulating apolipoprotein M. J Biol Chem. 283:16940–16949. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Luo G, Zhang X, Mu Q, et al: Expression
and localization of apolipoprotein M in human colorectal tissues.
Lipids Health Dis. 9:1022010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gu JG, Zhu CL, Cheng DZ, Xie Y, Liu F and
Zhou X: Enchanced levels of apolipoprotein M during HBV infection
feedback suppresses HBV replication. Lipids Health Dis. 10:1542011.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jiang J, Wu C, Luo G, et al: Expression of
apolipoprotein M in human hepatocellular carcinoma tissues. Acta
Histochem. 113:53–57. 2011. View Article : Google Scholar
|
|
76
|
Xu X, Ye Q, Xu N, et al: Effects of
ischemia-reperfusion injury on apolipoprotein M expression in the
liver. Transplant Proc. 38:2769–2773. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Park YJ, Yoo SA, Lee JH, Chung YJ, Cho CS
and Kim W: The APOM polymorphism as a novel risk factor for
dyslipidaemia in rheumatoid arthritis: a possible shared link
between disease susceptibility and dyslipidaemia. Clin Exp
Rheumatol. 31:180–188. 2013.
|
|
78
|
Zhao DX, He ZY, Qin X, et al: Association
of apolipoprotein M gene polymorphisms with ischemic stroke in a
Han Chinese population. J Mol Neurosci. 43:370–375. 2011.
View Article : Google Scholar
|
|
79
|
Burkart KM, Manichaikul A, Wilk JB, et al:
APOM and high-density lipoprotein cholesterol are associated with
lung function and per cent emphysema. Eur Respir J. 43:1003–1017.
2014. View Article : Google Scholar :
|
|
80
|
Kim J, Lee S, In K, et al: Increase in
serum haptoglobin and apolipoprotein M in patients with obstructive
sleep apnoea. J Sleep Res. 18:313–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Dullaart RP, Plomgaard P, de Vries R,
Dahlbäck B and Nielsen LB: Plasma apolipoprotein M is reduced in
metabolic syndrome but does not predict intima media thickness.
Clin Chim Acta. 406:129–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ahnström J, Gottsäter A, Lindblad B and
Dahlbäck B: Plasma concentrations of apolipoproteins A-I, B and M
in patients with abdominal aortic aneurysms. Clin Biochem.
43:407–410. 2010. View Article : Google Scholar
|
|
83
|
Ahnström J, Gottsater A, Lindblad B and
Dahlbäck B: Plasma concentrations of apolipoproteins A-I, B and M
in patients with critical limb ischemia. Clin Biochem. 43:599–603.
2010. View Article : Google Scholar
|
